Cystic Fibrosis Foundation Announces Rowe as Next Chief Scientific Officer
Steve Rowe, M.D., MSPH, Professor in the Division of Pulmonary, Allergy, and Critical Care Medicine
The Department of Medicine is excited to congratulate Steve Rowe, M.D., MSPH, (Professor, Pulmonary, Allergy and Critical Care Medicine) on his new position as Chief Scientific Officer for the Cystic Fibrosis Foundation—the world’s leader in the search for a cure for cystic fibrosis—effective July 1, 2022. As the CF Foundation’s Chief Scientific Officer, Rowe will oversee the direction and execution of their core scientific strategy which aims to find a cure for all patients with cystic fibrosis. Congratulations on this exciting opportunity, Dr. Rowe!
Read moreBirket and Erdmann Are 2022 Pittman Scholars
The Department of Medicine's Susan Birket, Ph.D., (Assistant Professor, Pulmonary, Allergy and Critical Care Medicine) and Nathan Erdmann, M.D., Ph.D., (Assistant Professor, Infectious Disease) are named among the 2022 James A. Pittman Jr., M.D., Scholars. The program recognizes junior faculty and supports the recruitment and retention of highly competitive scientists and physician-scientists. Each award recipient will receive $12,500 per year for the next three years in support of continued discovery in the basic or clinical sciences. Congratulations, Drs. Birket and Erdmann on this well-deserved recognition. .
Read moreLee Reports Experimental Gel Creates “Lifeline” for Patients Needing Dialysis
Pictured Above (L to R): Brigitta Brott, M.D., (Cardiovascular Disease), Timmy Lee, M.D., (Nephrology), Joseph Garner, Ph.D., (Biotechnology Program), Patrick Hwang, Ph.D., and Ho-Wook Jun, Ph.D. (Biomedical Engineering)
Timmy Lee, M.D., (Professor, Nephrology) and colleagues co-authored a report in the journal Biomaterials showing that an experimental nanomatrix gel improves the development of arteriovenous fistula, which provides stable vascular access for patients who require hemodialysis. Experts say this discovery holds promise for more than 600,000 patients in the U.S. with end stage kidney disease.
Read moreNew Gene Therapy Could Provide Cure for Sickle Cell Disease
Above: Julie Kanter, M.D., Associate Professor in the Division of Hematology and Oncology and Co-Director of the UAB Lifespan Comprehensive Sickle Cell Center
Julie Kanter, M.D., (Associate Professor, Hematology and Oncology; Co-director of the UAB Lifespan Comprehensive Sickle Cell Center) and colleagues have been published in the New England Journal of Medicine. After six months of treatment with the new gene therapy LentiGlobin, clinical trial participants started making more normal hemoglobin than sickled hemoglobin, which has protected them from experiencing painful blockages in their small blood vessels. This treatment holds tremendous promise of an ultimate cure for patients with sickle cell disease, the most common form of inherited blood disorder. Great work, Dr. Kanter!
Read moreDOM Celebrates 2021 Fellowship Match Results
Above, a few of our residents who matched into fellowship. First row: Myles Prados (ID), Catherine Lumb (Geriatrics), Lindsey Shipley (Gastroenterology) Back row: Sal Kamal (GIM), Tylan Magnusson (Hem/Onc), Tarek Abdalla (ID), Will Morgan (Cardiology)
The Department of Medicine is proud to announce a 100 percent match rate for internal medicine residents who applied to fellowship this year, with 13 of the 27 applicants staying right here at UAB for their specialty training. Additionally, we are delighted to report a diversity milestone in recruiting all-female fellows to join our Endocrinology and Gastroenterology fellowship programs next year. Congratulations all around!
Read more